Comparisons of Treatment Responses of Early Syphilis to 2.4 Milliunits (MU) Single-dose Benzathine Penicillin G With or Without Doxycycline in People Living With HIV

This randomized controlled superiority study will be conducted during 2023-2025. The eligible participants are adult people living with HIV (PLWH) who are newly diagnosed with early syphilis. Participants will be randomized in a 1:1 ratio to receive single-dose benzathine penicillin G (BPG) (2.4 MU intramuscularly once) plus doxycycline (100 mg orally twice daily for 7 days) or single-dose BPG. The primary outcome is serologic response, defined as a decline of rapid plasma reagin (RPR) titer by 4-fold or greater, at week 24 and week 48; and the secondary outcomes include microbiologic response of syphilis and bacterial sexually transmitted infections (STIs) assessed by nucleic-acid amplification test (NAAT) at week 4.

开始日期2024-01-01

申办/合作机构

National Taiwan University Hospital

[+6]

ACTRN12624000333516 / Recruiting临床2期

Safety, tolerability and acceptability of high dose, subcutaneous injection of benzathine penicillin G (Bicillin® L-A) in children and young adults with rheumatic fever

开始日期2023-06-01

申办/合作机构

University of Otago

NCT05980871 / Active, not recruiting临床4期IIT

Treatment Responses of Early Syphilis to Single-dose Ceftriaxone Plus Doxycycline Versus Single-dose Benzathine Penicillin G Plus Doxycycline in PLWH

In a prospective study investigating the prevalence of STIs among at-risk PLWH, the prevalence of Chlamydia trachomatis and N. gonorrhoeae was 24.7% and 12.1%, respectively. Surprisingly, the study found high rates of C. trachomatis and/or N. gonorrhoeae co-infections in PLWH with recent hepatitis C virus (HCV) infection (50%), HBsAg positivity (44%), and early syphilis (36%). Considering the high rate of sexually transmitted co-infections, combination therapy of single-dose ceftriaxone plus 7-day doxycycline for early syphilis may provide convenience and benefit to treatment of N. gonorrhoeae and C. trachomatis co-infections at a single clinic encounter. In the present study, this study aim to compare the efficacy of ceftriaxone plus doxycycline versus BPG plus doxycycline as the treatment for early syphilis among PLWH.

开始日期2023-03-10

申办/合作机构

National Taiwan University Hospital

100 项与苄星青霉素相关的临床结果

登录后查看更多信息

100 项与苄星青霉素相关的转化医学

登录后查看更多信息

100 项与苄星青霉素相关的专利（医药）

登录后查看更多信息

542

项与苄星青霉素相关的文献（医药）

2025-01-01·THERIOGENOLOGY

Serial frequent or multiple Tru-cut® testicular biopsies in rams enable assessment of histological characteristics or transcriptional profiles, with no acute or chronic adverse effects

Article

作者: Pupulim, A.G.R. ; Rattes, P Z ; Kastelic, J.P. ; Pupulim, A G R ; Kastelic, J P ; Uzae, K Z ; Ribeiro, G.C. ; Nogueira, G P ; Mogollón García, H D ; Denadai, R ; Nunes, S G ; Uzae, K.Z. ; Ferreira, J C P ; Navolar, F.M.N. ; Di Santis, G.W. ; Nogueira, G.P. ; Rizzoto, G. ; Carvalho, J.C. ; Navolar, F M N ; Ferreira, J.C.P. ; Rattes, P.Z. ; Castilho, A C S ; Denadai, R. ; Nunes, S.G. ; Ribeiro, G C ; Rizzoto, G ; Mogollón García, H.D. ; Di Santis, G W ; Carvalho, J C ; Castilho, A.C.S.

This study aimed to evaluate the feasibility of performing multiple testicular biopsies in rams using Tru-cut® needles, assessing histological structure, gene expression, and potential complications such as effects on semen quality, testicular blood flow, and ultrasonographic echotexture. In Exp. 1, six mature rams underwent testicular biopsies at intervals (0, 3, 6, 12, 24, and 48 h) using a 16 G Tru-cut® needle, with alternating testes for each collection. Benzathine benzylpenicillin and flunixin meglumine were administered for infection and inflammation control. Local anesthesia and post-biopsy care included lidocaine, digital pressure, and ice application. Testicular samples were analyzed for gene expression related to inflammation, oxidative stress, and steroidogenesis. Semen quality was assessed pre-biopsy and 28 days post-biopsy. Ultrasonographic evaluations of the scrotum and testes were conducted before biopsies and on days 5, 9, 13, 17, and 21 post-biopsies. In Exp. 2, a second group of six mature rams underwent biopsies using 14 G needles, with two samples taken from each testis. Samples were histologically examined for structural preservation. Scrotal skin temperature was measured using infrared thermography, and testicular blood flow was assessed via color Doppler ultrasonography, with measurements taken before and on days 1, 2, 4, 6, 8, 10, 25, 50, 75, and 100 post-biopsies. Semen collection followed the same schedule as in Exp. 1. In Exp. 3, biopsies were performed on different testicular regions (upper, middle, lower) using 12 G, 14 G, and 16 G needles to compare structural preservation. Samples were histologically analyzed. No clinical signs of injury, inflammation, or fluid accumulation were observed. Scrotal pain, increased temperature, swelling, and bleeding were absent, and behavioral signs indicative of pain were not detected. Gene expression remained unchanged, and no significant alterations in seminal characteristics or testicular echogenicity were observed. A slight increase in resistivity and pulsatility indices was noted in Exp. 2. Biopsies with 14 G and 16 G needles resulted in structural disruptions, while 12 G needles better preserved testicular parenchyma. Multiple testicular biopsies using Tru-cut® needles did not cause significant morphological changes, alter transcriptional profiles, or affect semen or ultrasonographic characteristics, demonstrating that this method is viable for monitoring acute molecular changes in the testes.

2024-11-01·INTERNATIONAL JOURNAL OF DERMATOLOGY

Ulcerative erythematous papules and plaques on the face and lower legs of a man living with HIV: a clinicopathological challenge

Article

作者: Coates, Sarah J. ; Hickey, Matthew D. ; De la Sancha, Carlo ; Leslie, Kieron S. ; McKenzie, Ning C.

Abstract:

A 44‐year‐old male presented with a 2‐month history of erythematous ulcerative papules and plaques on the scalp, face, and bilateral lower legs. He had a 5‐year history of well‐controlled HIV on antiretroviral therapy and recurrent syphilis infections. His face had violaceous plaques, while bilateral ankles and calves had ulcerative lesions with necrotic centers and purple borders. The morphologies clinically mimicked pyoderma gangrenosum on the lower extremities and cutaneous lymphoma on the face. Biopsy and reactive rapid plasma reagin confirmed a diagnosis of lues maligna, and the patient was successfully treated with penicillin G benzathine.

2024-10-01·JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics and Safety of Intramuscular Injectable Benzathine Penicillin G in Japanese Healthy Participants

Article

作者: Raber, Susan ; Nagashima, Masahito ; Muto, Chieko ; Li, Yinhua ; Okayama, Akifumi ; Hagi, Toshiaki

Abstract:

An intramuscular (IM) suspension of benzathine penicillin G (BPG) has been used as first‐line therapy for the treatment of syphilis worldwide since its approval in the 1950s. However, there are limited reports about the pharmacokinetics of BPG. A Phase 1 study was conducted on eight Japanese healthy participants to investigate the pharmacokinetics (samples collected predose to 648 h post‐dose) and safety of 2.4 million units of BPG after a single IM injection. Following administration, penicillin G, the active moiety of BPG, was absorbed slowly from the injection site with a median time to Cmax (tmax) of 48 h post‐dose. After the achievement of Cmax, concentrations of penicillin G declined slowly in a monophasic fashion with a mean apparent terminal half‐life of 189 h. Geometric mean AUCinf and Cmax were 50770 ng•h/mL and 259 ng/mL, respectively. Median time (range) above the well‐accepted therapeutic concentration (18 ng/mL) for syphilis treatment was 561 h (439‐608 h [18‐25 days]), which reached and exceeded the necessary duration of 7‐10 days for syphilis treatment. Two participants were underdosed with residual drug left in the syringe due to the high viscosity of the drug product. Only one (12.5%) participant reported a mild adverse event of nasopharyngitis, which was considered not related to the study treatment. The study results supported BPG approval in Japan as an option for syphilis treatment.

项与苄星青霉素相关的新闻（医药）

2024-11-12

·drugs

Genomic Test Might Quickly Diagnose Any Type of Infection

TUESDAY, Nov. 12, 2024 -- A cutting-edge genetic test can rapidly detect and identify almost any kind of disease-causing microorganism in the human body, whether it’s a virus, bacteria, fungus or parasite, researchers say. Doctors have been using the genetic test for more than a decade to identify pathogens in spinal fluid, after its development at the University of California-San Francisco. And now researchers have adapted the test to identify germs in respiratory fluid that can cause pneumonia, according to a new study published Nov. 12 in the journal Nature Medicine . The research team also has automated the test, which is called metagenomic next-generation sequencing or mNGS, the study says. The new respiratory version of the mNGS test requires just 30 minutes of hands-on time before robots and AI take over, and can return results in time to treat dangerous infections, researchers said. “Our goal was to have the entire process completed within 12 to 24 hours, giving a same-day or next-day result,” senior researcher Dr. Charles Chiu , a professor of laboratory medicine and infectious diseases at UCSF, said in a news release. The mNGS test takes a bare-knuckled approach to analysis. Rather than looking for single types of pathogen one by one, the test analyzes all RNA and DNA that are present in a sample, then separates human genetic material from those that originate in bacteria, viruses, fungi or parasites. “Our technology is deceptively simple,” Chiu said. “By replacing multiple tests with a single test, we can take the lengthy guesswork out of diagnosing and treating infections.” The mNGS test first made waves back in 2014 when doctors used it to save the life of then-15-year-old Joshua Osborn, who’d come down with debilitating headaches, fever, weight loss and fatigue. Osborn, who lived in Cottage Grove, Wisc., eventually fell into a coma with life-threatening encephalitis – and still no one could figure out what was making him sick. Medical tests and a brain biopsy brought back nothing. But once mNGS was employed, the test sussed out the cause within 48 hours. It wound up being Leptospira santarosai , a bacterial species native to Puerto Rico. As it turns out, Osborn and his family had visited a church camp there a year before his hospitalization. The remedy for the disease, that had plagued him for more than a year, wound up being old-fashioned penicillin. “I’m happy to be living,” Osborn said at the time. “By the percentages, the likelihood is pretty much that I wouldn’t be. I’m thankful.” Between 2016 and 2023, the UCSF team analyzed nearly 5,000 spinal fluid samples with the test, more than 14% of which turned out to have an infection. Overall, the test accurately identified the pathogen in spinal fluid 86% of the time, researchers say in their new paper. “Our mNGS test performs better than any other category of test for neurologic infections,” Chiu said, “The results support its use as a critical part of the diagnostic armamentarium for physicians who are working up patients with infectious diseases.” Based on these results, researchers have adapted the test to serve as a rapid-response system for respiratory diseases that could become the basis of the world’s next pandemic. The new report shows that the test can detect respiratory viruses like COVID, influenza and RSV in less than a day, even if there’s only small amounts of virus present in a sample. The test also should be able to detect strains expected to emerge in the future. Both the spinal fluid and respiratory droplet versions of the mNGS test have received breakthrough device designation from the U.S. Food and Drug Administration, placing them on a fast track for full approval. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

突破性疗法临床研究

2024-10-22

·PRNewswire

Two Scientists Win March of Dimes Basil O'Connor Grants to Advance Artificial Womb for Preterm Babies, Sickle Cell Screening for Newborns in Sub-Saharan Africa

ARLINGTON, Va., Oct. 22, 2024 /PRNewswire/ -- March of Dimes, the leading organization fighting for the health of all moms and babies, has awarded two physician-scientists the Basil O'Connor Starter Scholar Research Award, the organization's signature grants for up-and-coming scientists embarking on lifelong research paths. Continue Reading Dr. Emily Partridge, MD, PhD, MHS, a pediatric and fetal surgeon at The Children's Hospital of Philadelphia (CHOP) and an assistant professor of surgery at the University of Pennsylvania, and Dr. Hojun Li, MD, PhD, a pediatric hematologist and assistant professor of pediatrics at the University of California, San Diego, each received $150,000 grants. "Our Basil O'Connor awards have a rich history, with past winners going on to make truly outstanding achievements." Post this Dr. Partridge's work will build upon her existing research to advance the artificial womb, a fluid-filled sac modeled after the uterus made to improve developmental outcomes for extremely preterm babies, those babies born at or before 25 weeks of pregnancy. Her research focuses on adding liquid ventilation to the womb's breathing mechanism. This process uses a special chemical in the baby's lungs to aid breathing, prevent infections and strengthen the lungs in preparation for withdrawal from the artificial womb. Dr. Partridge anticipates that once the baby is out of the artificial womb, they will continue to use the liquid ventilation to further strengthen their lungs before placement on a regular ventilator in the neonatal intensive care unit. Dr. Li will use his grant to build upon the creation of a simple, portable, and effective test that will identify newborns with sickle cell anemia, a condition that impacts about 1 in 2,000 babies in the US and more acutely impacts people of African descent. Sickle cell disease causes mutant hemoglobin molecules to stretch out red blood cells, making them unable to fit through blood vessels and deliver oxygen, ultimately leading to infections, severe pain, stroke, and other life-threatening conditions. His test will focus on babies born in Sub-Saharan Africa, where 250,000 babies are born each year with the condition, with 95% of those dying in the first five years due to infection and other sickle-cell-related complications. The test developed by Dr. Li and then Massachusetts Institute of Technology master's student Amelia Seabold, now at University of Oxford in England, along with others, will use genome editing technology CRISPR to identify the mutated sickle cell gene within minutes from a single drop of blood. Dr. Li's goal is to see the test distributed to health workers in Sub-Saharan Africa who make home visits to postpartum moms. Babies diagnosed with the disease can be given penicillin, which promises to dramatically improve life expectancy and quality of life. "Our Basil O'Connor awards have a rich history, with past winners going on to make truly outstanding achievements in the field of maternal and infant health," said March of Dimes Chief Scientific Advisor Dr. Emre Seli. "Drs. Partridge and Li are two shining stars in our field, and we couldn't be prouder to support their work for preterm babies and those with sickle cell disease. Their vital research is poised not only to dramatically change outcomes for moms and babies globally, but to pave new scientific paths for the young physician-scientists who walk in their footsteps to reduce preventable maternal and infant mortality and morbidity." The Basil O'Connor awards, named for the first March of Dimes chairman and president, are part of March of Dimes' research strategy to address the multi-faceted nature of the maternal and infant health crisis with funding that supports discovery, translational and social science research, and data collection and analysis. Find more information about the Basil O'Connor Awards here. About March of Dimes March of Dimes leads the fight for the health of all moms and babies. We support research, education, and advocacy, and provide programs and services so that every family can have the best possible start. Since 1938, we've built a successful legacy to support every pregnant person and every family. Visit marchofdimes.org or nacersano.org for more information. Find us on Facebook and follow us with #marchofdimes and @marchofdimes. SOURCE March of Dimes Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024-09-13

·PRNewswire

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Approval underscores CSL and Arcturus Therapeutics' commitment to delivering disruptive technologies to combat COVID-19 and other respiratory viral diseases to protect public health KOSTAIVE®, the world's first self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, was approved for adults 18 years of age and older in November 2023 The updated sa-mRNA COVID-19 vaccine is tailored to protect against the JN.1 lineage of Omicron subvariants Meiji Seika Pharma, CSL's exclusive partner in Japan, will begin vaccine distribution in time for the October COVID-19 vaccination campaign CSL and Arcturus Therapeutics' partnership delivers on the promise to advance innovative vaccine technology for viral respiratory diseases KING OF PRUSSIA, Pa. and SAN DIEGO, Sept. 13, 2024 /PRNewswire/ -- Global biotechnology leader CSL (ASX:CSL; USOTC:CSLLY) and sa-mRNA pioneer Arcturus Therapeutics today announced that Japan's Ministry of Health, Labor and Welfare (MHLWs) granted approval and authorization for their updated self-amplifying mRNA (sa-mRNA) COVID-19 vaccine, KOSTAIVE®. The updated vaccine is targeted to protect against the JN.1 lineage of Omicron subvariants for adults 18 years of age and older. Continue Reading Arcturus Therapeutics (PRNewsfoto/CSL) CSL's exclusive partner in Japan, Meiji Seika Pharma, will begin distributing the updated vaccine in time for the October COVID-19 vaccination campaign, marking the world's first commercially available sa-mRNA COVID-19 vaccine for adults 18 and older. In May 2024, a Japanese health ministry panel recommended that COVID-19 vaccines be updated to target the JN.1 lineage of Omicron subvariants for the 2024/2025 national immunization program. This aligns with recent recommendations from the World Health Organization. "We are pleased to receive the updated approval from Japan's Ministry of Health, Labor and Welfare, and remain on track to distribute KOSTAIVE® in time for the October COVID-19 vaccination campaign," said Emmanuelle Lecomte-Brisset, Senior Vice President and Head of Global Regulatory Affairs, CSL. "We look forward to introducing KOSTAIVE® in Japan as a safe, tolerable and more durable option in protecting against COVID-19." "We believe KOSTAIVE® has the potential to change the paradigm for COVID-19 vaccines in Japan," said Jonathan Edelman, M.D., Senior Vice President, Vaccines Innovation Unit, CSL. "Today's approval further demonstrates CSL's promise to pursue, develop and deliver new innovative treatment options to protect public health." The approval is based on clinical evidence supporting the safety and effectiveness of CSL and Arcturus Therapeutics' sa-mRNA COVID-19 vaccine, including published data demonstrating superior immunogenicity to Omicron BA 4/5 compared to a conventional mRNA COVID-19 vaccine booster and follow-up data demonstrating duration of immunity lasting up to one year. "We are pleased that our sa-mRNA technology will be available to vaccinate people in Japan against COVID-19, which remains an ongoing risk to public health around the world," said Joseph Payne, Chief Executive Officer of Arcturus Therapeutics. "We look forward to continuing to work with CSL and regulators to explore the development of KOSTAIVE® in additional countries." About sa-mRNA mRNA vaccines help protect against infectious diseases by providing a blueprint for cells in the body to make a protein to help our immune systems recognize and fight the disease. Unlike conventional mRNA vaccines, self-amplifying mRNA vaccines instruct the body to make more mRNA and protein to boost the immune response. About CSL CSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSLBehring.com/Vita and follow us on Twitter.com/CSL. For more information about CSL, visit . About Arcturus Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus' pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus' versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus' technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit . In addition, please connect with us on Twitter and LinkedIn. About Meiji Seika Pharma Co., Ltd. Meiji Seika Pharma, since it launched penicillin in 1946, has been providing efficacious and high-quality pharmaceutical products such as therapeutics and vaccines for infectious diseases, therapeutics for central nervous system diseases as well as generic drugs in response to various medical needs. As a leading company in the field of infectious diseases, we are strengthening our platform for infection control and prevention with vaccines and antimicrobial agents. Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical fact included in this press release, are forward-looking statements, including those regarding strategy, future operations, the planned launch of KOSTAIVE® in Japan, the distribution of the updated vaccine by Meiji Seika Pharma and timing thereof, the timing and likelihood of availability of doses of the updated vaccine in Japan, the continued demonstration of KOSTAIVE® as a safe, tolerable and more durable option against COVID-19, that preclinical or clinical data will be predictive of future clinical results, and the impact of general business and economic conditions. Arcturus may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not place undue reliance on such forward-looking statements. These statements are only current predictions or expectations, and are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements, including those discussed under the heading "Risk Factors" in Arcturus' most recent Annual Report on Form 10-K, and in subsequent filings with, or submissions to, the SEC, which are available on the SEC's website at . Except as otherwise required by law, Arcturus disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise. Media Contacts: CSL Media Contacts Sue Thorn Mobile: 617 799 3151 Email: [email protected] Australia: Jimmy Baker [email protected] +61 450 909 211 Asia Pacific: Hamish Walsh +61 422 424 338 [email protected] Arcturus Media Contact: Neda Safarzadeh VP, Head of IR/PR/Marketing [email protected] SOURCE CSL WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

疫苗上市批准信使RNA临床研究

100 项与苄星青霉素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02157	苄星青霉素	J01CE08	-

研发状态

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
梅毒	日本	Pfizer Japan, Inc.	2021-09-27
感染	中国	苏州二叶制药有限公司	1982-01-01
细菌感染	美国	King Pharmaceuticals LLC	1952-06-27

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


ATS2024	N/A	肺嗜酸性粒细胞增多	-	Ceftriaxone	糧夢襯壓積窪獵淵憲獵(顧觸網鹽壓鏇構齋膚簾) = 衊獵顧鏇鑰鑰獵鹽蓋鏇鹹夢醖選醖餘艱遞糧糧 (願淵選選餘衊鏇願壓夢 ) 更多	-	2024-05-19
EULAR2018	N/A	白塞病/贝赫切特综合征 \| 溃疡 Streptococcus	15	Benzathine Penicillin (BP)	憲網窪構鹹築糧淵鑰襯(選鹽齋鑰餘憲廠襯衊糧) = 遞製範簾遞鹽廠顧簾遞築蓋壓鹹遞鬱膚遞觸鹽 (艱選艱積壓網範製襯鏇 )	积极	2018-06-13
NCT02611765 (Pubmed)	临床4期	梅毒 \| HIV感染	64	Single-dose regimen of BPG	選觸繭遞淵壓簾構觸繭(淵網鏇蓋淵憲築鬱顧選) = 鑰遞顧窪網憲觸廠觸範蓋艱醖淵糧齋憲襯窪夢 (鑰獵餘餘夢築鹹顧膚鹹 )	-	2017-03-15
NCT02611765 (Pubmed)	临床4期	梅毒 \| HIV感染	64	3-dose regimen of BPG	選觸繭遞淵壓簾構觸繭(淵網鏇蓋淵憲築鬱顧選) = 鏇鹹製鏇憲範壓遞積繭蓋艱醖淵糧齋憲襯窪夢 (鑰獵餘餘夢築鹹顧膚鹹 )	-	2017-03-15
NCT02611765 (CTgov)	临床4期	梅毒 \| 合并感染	64	Benzathine penicillin G intramuscular 7.2 million units (Enhanced Therapy)	醖願齋壓鹽獵齋憲膚餘(襯衊願選築遞膚範壓獵) = 鑰鬱襯製憲構膚製積壓製簾鏇窪選鏇構獵蓋網 (醖膚淵觸顧壓衊醖憲憲, 齋繭膚齋鑰壓廠醖齋選 ~ 範艱鏇顧選製壓窪鑰顧) 更多	-	2016-04-11
NCT02611765 (CTgov)	临床4期	梅毒 \| 合并感染	64	Benzathine penicillin G intramuscular 2.4 million units (Standard Therapy)	醖願齋壓鹽獵齋憲膚餘(襯衊願選築遞膚範壓獵) = 窪艱糧繭鏇鏇膚齋壓鬱製簾鏇窪選鏇構獵蓋網 (醖膚淵觸顧壓衊醖憲憲, 糧積糧夢淵築鏇廠餘選 ~ 窪艱觸膚繭築範願選憲) 更多	-	2016-04-11